Technology | Contrast Media Injectors | February 16, 2016

Guerbet Receives FDA 510k Clearance for OptiOne Single-Head Contrast Delivery System

Entry-level injector offers advanced multipurpose functionality for CT imaging procedures

Guerbet, OptiOne single-head contrast delivery system, FDA 510k clearance

February 16, 2016 — Guerbet announced that it has received 510K clearance from the U.S. Food and Drug Administration (FDA) for its OptiOne Single-Head Contrast Delivery System, featuring advanced multipurpose functionality for computed tomography (CT) imaging procedures.

The OptiOne is an entry-level single-head injector launched in 2015 on the European market, available in ceiling-suspended and pedestal form. It is designed for the injection of radiopaque contrast agents in the vascular system of patients to obtain diagnostic images in CT scan examinations.

Guerbet will present the injector at the upcoming European Congress of Radiology (ECR), March 2-6 in Vienna.

The system combines ease of use, multipurpose functionality and optimized contrast media usage. It is designed to be adaptable to the workflow of the imaging department, providing a fully programmable powerhead with intuitive bedside operation and flexibility of use with the ability to accommodate prefilled or empty syringes.

The OptiOne is intended for use by doctors, radiology technologists and other licensed medical practitioners in a healthcare facility or hospital with CT equipment. Each injection is accomplished with a motor-driven syringe mechanism with microprocessor control of the flow rate, volume, pressure and timing. 

OptiOne is manufactured by Cincinnati, Ohio-based Liebel-Flarsheim, a company acquired by Guerbet as part of its purchase of Mallinckrodt's Contrast Media and Delivery Systems business announced on Nov. 27, 2015.

For more information: www.guerbet.com

Related Content

Videos | Computed Tomography (CT) | July 19, 2019
Quynh Truong, M.D., MPH, associate professor of radio
Low Doses of Radiation Promote Cancer-capable Cells
News | Radiation Dose Management | July 18, 2019
Low doses of radiation equivalent to three computed tomography (CT) scans, which are considered safe, give cancer-...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
New Lung Ambition Alliance Aims to Double Five-year Lung Cancer Survival by 2025
News | Lung Cancer | July 17, 2019
The International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (...
Example of an intentionally truncated CT image

Figure 1: Example of an intentionally truncated CT image. The truncation percentage was calculated as the ratio of the patient border touching the field of view to the total patient border (red/(read+blue)). Image courtesy of Qaelum.

Feature | Radiation Dose Management | July 15, 2019 | Niki Fitousi, Ph.D., and An Dedulle
One of the main benefits of a radiation dose management system is the possibility to automatically generate alerts when...
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
Routine scan of abdomen pelvis taken with the UW-Madison’s Revolution 256 CT scanner using the FDA-cleared reconstruction algorithm, called TrueFidelity.

Routine scan of abdomen pelvis taken with the UW-Madison’s Revolution 256 CT scanner using the FDA-cleared reconstruction algorithm, called TrueFidelity. UW-Madison was the first site in the U.S. to get this technology. Its use is now being integrated into UW CT protocols. Image courtesy of Timothy P. Szczykutowicz

Feature | Computed Tomography (CT) | July 12, 2019 | By Greg Freiherr
When providers develop their own imaging protocols, they are wasting time and money, according to...
Mednax National Cardiac Centers of Excellence Program Highlighted at SCCT 2019
News | CT Angiography (CTA) | July 11, 2019
Mednax Inc. and Mednax Radiology Solutions announced that Chief Medical Officer Ricardo C. Cury, M.D., FSCCT, will...
Achenbach to Receive Inaugural 2019 Stephan Achenbach Pioneer Award in Cardiovascular CT
News | Cardiac Imaging | July 10, 2019
The Society of Cardiovascular Computed Tomography (SCCT) will present Stephan Achenbach, M.D., FSCCT with the inaugural...